ライフサイエンスコーパス: PCV7

1 PCV7 and PCV13 were implemented in Israel in July 2009 a

2 PCV7 induces a greater functional antibody response than

3 PCV7 introduction resulted in 83% (95% CI, 66%-91%, P <

4 PCV7-serotype IPD declined among all race, age, and PPV2

5 PCV7-type IPD rates in all ages in both races decreased

6 PCV7/PCV13 implementation resulted in a marked decline i

7 PCV7/PCV13 implementation resulted in a marked decline i

8 PCV7/PCV13 were implemented in Israel in July 2009/Novem

9 ious analysis to 6.5 years after the "3 + 0" PCV7 schedule was introduced in Australia in 2005.

10 A 2 + 1 PCV7 schedule was effective in preventing vaccine-seroty

11 We estimated the effectiveness of >/=2 PCV7 doses against invasive pneumococcal disease (IPD) i

12 Effectiveness of >/=2 PCV7 doses against vaccine-serotype IPD was 74% (95% con

13 at before (1998-2000) and during (2001-2002) PCV7 introduction.

14 In 2006-2007, PCV7 types caused 2% of IPD cases, and the 6 additional

15 Priming with 1, 2, or 3 PCV7 doses during infancy did not affect serotype-specif

16 19F, and similar or lower responses for 6/7 PCV7 serotypes.

17 alysis population included 881 PCV13 and 873 PCV7 recipients.

18 Expected annual rates of IPD absent PCV7 introduction were estimated by extrapolation using

19 OM rates decreased, along with an additional PCV7 + 6A OM reduction.

20 tions increased from 51% before to 61% after PCV7 introduction (P < .0001).

21 o PCV7 serotypes decreased in all ages after PCV7 introduction (P < .001), whereas the incidence of I

22 nce and carriage prevalence before and after PCV7 introduction to estimate changes in serotype-specif

23 We compared rates before and after PCV7 use by age, race, PPV23 indication, and serotype.

24 Of the 256 cases diagnosed after PCV7 introduction, 23% (n = 60) had been born before 37

25 Dramatic reductions in IPD after PCV7 introduction in the United States remain evident 7

26 n serotype-specific invasive potential after PCV7 introduction.

27 of PCV13 disease, was observed shortly after PCV7/PCV13 introduction.

28 cific IPD changes among multiple sites after PCV7 introduction.

29 data >/= 2 years before and >/= 1 year after PCV7 introduction.

30 quickly and were sustained for 7 years after PCV7 introduction, supporting use of PCVs.

31 Vaccine effectiveness against PCV7-serotype invasive pneumococcal disease was 87% (95%

32 d greater PCV13-conferred protection against PCV7-targeted serotypes than the 6 PCV13-only serotypes.

33 d greater PCV13-conferred protection against PCV7-targeted serotypes than the six PCV13-only serotype

34 a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additional serotypes (PCV6+).

35 n H. influenzae and S. aureus carriage among PCV7 recipients.

36 AOM and after exposure to antimicrobials and PCV7, which is mainly attributable to reduced prevalence

37 [CI], 12.0-14.0) per 100 000 live births and PCV7 serotypes accounted for 44% (154/349) of serotyped

38 Overall and PCV7-type IPD incidence declined by 45% (from 24.4 to 13

39 d outcomes of IPD in children with PCV13 and PCV7 vaccine failure.

40 The vaccine effectiveness for PCV13 and PCV7 was lower than predicted by the aggregate correlate

41 ease were serotype 19F, present in PCV13 and PCV7, and serotypes 6A and 19A, present in PCV13 only.

42 Protection against PCV13-serotype and PCV7-serotype CAAP was 67.0% (-424.3-100.0%) and 67.7% (

43 % (-191.4-100.0%) against PCV13-serotype and PCV7-serotype CAAP.

44 ve pressures of widespread macrolide use and PCV7 and PCV13 introductions on S. pneumoniae were assoc

45 dence in 2007 with that in 1998-1999 (before PCV7) and assessed potential serotype coverage of new co

46 an expected on the basis of the rates before PCV7 was introduced.

47 months or >=4 episodes in 12 months) between PCV7- and PCV13-era birth cohorts.

48 ttern: In the PCV7 period, only OM caused by PCV7 + 6A serotypes was decreased; in the PCV13 period,

49 mpared with the pre-PCV period, OM caused by PCV7 plus serotype 6A and the 5 additional PCV13 serotyp

50 er 100,000 person-years in disease caused by PCV7 serotypes (-89%; 95% confidence interval [CI], -92

51 Reductions in the rates of disease caused by PCV7 serotypes among both children and adults most likel

52 e of invasive pneumococcal disease caused by PCV7 serotypes decreased by 85% (95% CI, -89 to -79), wh

53 type, 0.16 (0.07-0.40) for disease caused by PCV7 serotypes, 0.17 (0.07-0.42) for disease caused by 1

54 gher proportion of adult IPD cases caused by PCV7 serotypes.

55 ng adults aged >40 years that were caused by PCV7-targeted serotypes.

56 an 86% reduction of the serotypes covered by PCV7 (1.46 vs 0.20 per 100,000; IRR 0.14, 0.10-0.18) and

57 The herd protection induced by PCV7 is continuing, and similar indirect protection is o

58 disease that exceeds protection provided by PCV7.

59 ody titers against the 7 serotypes shared by PCV7, PCV13, and PSV23.

60 titers against the seven serotypes shared by PCV7, PCV13, and PSV23.

61 e cross-reacting serotype 6C; and the common PCV7 serotype 19F.

62 The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal disease

63 the 7-valent pneumococcal protein conjugate (PCV7) vaccine, which includes serotypes 4, 6B, 9V, 14, 1

64 of children that did not complete the 4-dose PCV7 series had a higher proportion of adult IPD cases c

65 After 3 vaccine doses, PCV7 and PCV13 failure rates were 0.19/100000 (95% confi

66 in the pre-universal PCV7 (2002-2004), early PCV7 (2005-2007), pre-PCV13 (2008 to mid-2011), and post

67 in the pre-universal PCV7 (2002-2004), early-PCV7 (2005-2007), pre-PCV13 (2008-mid 2011) and post-PCV

68 Following PCV7 introduction, clinical information was also obtaine

69 ibe their clinical characteristics following PCV7 introduction.

70 CAAP rates markedly declined following PCV7/PCV13 introduction worldwide.

71 Replacement disease following PCV7 introduction was mainly due to serotypes 1, 3, 7F,

72 d overall changes in IPD incidence following PCV7 introduction for most studies, while the more detai

73 rotype 19A significantly increased following PCV7's introduction, but the incidence declined toward b

74 ther changes in rates had occurred following PCV7 introduction, we calculated site specific rate rati

75 italizations in children aged <1 y following PCV7 introduction (-18.0%, 95% CI: -22.6%, -13.1%, for 2

76 , 0.12 (0.08-0.20), and 0.18 (0.15-0.21) for PCV7+6A serotypes, 5 additional PCV13 serotypes, and all

77 dible interval: 79-97%) and 80% (46-93%) for PCV7/13 serotypes among Bedouin and Jewish children <12

78 Young infants have benefited from PCV7 through indirect (herd) protection.

79 uctions in IPD due to vaccine serotypes from PCV7 (IRR, 0.20; CI, .17-.22) were about 2-fold greater

80 n IPD incidence shortly after the shift from PCV7 to PCV13 in the national immunization program.

81 In France, the switch from PCV7 to 13-valent pneumococcal conjugate vaccine (PCV13)

82 The transition from PCV7 to PCV13 was associated with a decline of OM among

83 ected among children younger than 5 years if PCV7 alone had been continued, incidence of IPD overall

84 ased but remain low relative to decreases in PCV7-type IPD.

85 ed by serotypes included in PCV13 but not in PCV7 decreased from 6.5 to 0.5 per 100 000 in children a

86 ined in the 13-valent PCV (PCV13) but not in PCV7.

87 83% (95% CI, 66%-91%, P < .001) reduction in PCV7 IPD and a declining trend in overall IPD by 2009-20

88 We measured the effects of trends in PCV7-type and non-PCV7-type IPD rates on racial disparit

89 in conjugate (PCV13) vaccine, which includes PCV7 serotypes plus serotypes 1, 3, 5, 6A, 7F, 19A, may

90 The Gambia introduced PCV7 in August, 2009, and PCV13 in May, 2011.

91 95% IE] 59-68) and IPD caused by PCV13 minus PCV7 serotypes declined by 93% (91-94), by July, 2012, t

92 ined by 12-32% and IPD caused by PCV13 minus PCV7 type IPD declined by 58-72%, depending on age.

93 gainst which PCV7 has no effect (PCV13 minus PCV7).

94 and nonsusceptibility to penicillin of non- PCV7 serotypes, and we found increased proportions of sp

95 d the effects of trends in PCV7-type and non-PCV7-type IPD rates on racial disparities in overall IPD

96 sparities in IPD rates persisted because non-PCV7-type IPD rates are higher among blacks.

97 recent increase in meningitis caused by non-PCV7 serotypes, including strains nonsusceptible to anti

98 ingitis and invasive pneumonia caused by non-PCV7 types increased for all age groups (P< .05), wherea

99 s increased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use.

100 The percentages of cases from non-PCV7 serotypes 19A, 22F, and 35B each increased signific

101 ction of PCV7 resulted in an increase in non-PCV7 serotypes, including some not covered by the 13-val

102 disease (IPD) and moderate increases in non-PCV7 type IPD.

103 ever, rates of antibiotic-nonsusceptible non-PCV7-type IPD increased during 2004-2009.

104 D rates caused by serotype 19A and other non-PCV7 types have increased but remain low relative to dec

105 In Indigenous people, baseline PCV13 non-PCV7 IPD incidence was 3-fold higher, amplified by a ser

106 During 2007-2008, serotypes in PCV13 but not PCV7 caused 78%-97% of penicillin-nonsusceptible IPD, de

107 aused by serotypes included in PCV13 but not PCV7 were prevented among children aged <5 years (-97% d

108 cination were extrapolated based on observed PCV7 effects.

109 Nasopharyngeal carriage of PCV7 and 23vPPV serotypes was similar among the groups.

110 Nasopharyngeal carriage of PCV7 serotypes in Group 1 was significantly higher than

111 During the decade of PCV7 use (2000-2009), MR-IPD decreased rapidly until 200

112 A single dose of PCV7 induced significant increases in serotype-specific

113 the population that received 3 or 4 doses of PCV7 (mean centered), and a linear spline to control for

114 s after they were given two priming doses of PCV7 (n=126) or PCV13 (n=237) and opsonophagocytic antib

115 Despite near elimination of PCV7-type IPD in both races, overall disparities in IPD

116 In this study, the impact of PCV7 and PCV13 on MR-IPD was prospectively assessed.

117 with the observed heterogeneity in impact of PCV7 on childhood all-serotype IPD.

118 are the main determinants for the impact of PCV7 on childhood IPD and can be combined in a simple mo

119 l performance against the reported impact of PCV7 on childhood IPD in high-income countries from a re

120 vaccine serotypes may mitigate the impact of PCV7 on nasopharyngeal bacterial community structure and

121 We aimed at assessing the impact of PCV7/PCV13 sequential introduction on pneumococcal and o

122 eillance project following implementation of PCV7 (in September 2006) and PCV13 (in April 2010) in ch

123 etermined how the sequential introduction of PCV7 (2006) and PCV13 (2011) in the Norwegian childhood

124 e of IPD associated with the introduction of PCV7 (2007) and PCV13 (2010) while controlling for serot

125 conducted before nationwide introduction of PCV7 (2009) and PCV13 (2011).

126 Following the introduction of PCV7 and PCV13 in children, the net impact of serotype r

127 In Utah, the introduction of PCV7 and PCV13 was associated with rapid increases in se

128 Introduction of PCV7 in the Dutch National Immunization Program in 2006

129 Thus, the introduction of PCV7 resulted in an increase in non-PCV7 serotypes, incl

130 997 through 1999 (before the introduction of PCV7) and from 2007 through 2009 (well after its introdu

131 in gene diversity after the introduction of PCV7, the accessory gene pool re-expanded mainly by gene

132 s coded as RSV following the introduction of PCV7.

133 during the decade after the introduction of PCV7.

134 persists a decade after the introduction of PCV7.

135 ombination that predated the introduction of PCV7.

136 cluded data from an earlier investigation of PCV7 to assess vaccine effectiveness in children exposed

137 ng adults 25 to 44 years of age, the rate of PCV7-serotype disease declined by 57% (95% CI, -63 to -5

138 Rates of PCV7-serotype meningitis declined from 0.66 case to 0.18

139 Receipt of PCV7 resulted in pneumococcal serotype replacement but d

140 riage to disease before and after rollout of PCV7/13, measured as OM incidence per carrier.

141 f progression to complex OM after rollout of PCV7/13.

142 nontarget groups demonstrates the success of PCV7 and PCV13.

143 ALY) lost from the IPD remaining when use of PCV7 stopped in 2010 was estimated for the serotypes cov

144 AOM microbiology has changed with use of PCV7.

145 ere randomized to receive PPSV23 (n = 90) or PCV7 (1.0 mL; n = 91).

146 domly assigned to receive PCV13 (n = 932) or PCV7 (n = 934) at ages 2, 4, 6, or 12 months.

147 was higher than the efficacy of TIV alone or PCV7 alone.

148 For serotype 3, and the other PCV7 serotypes, there were no significant differences be

149 PCV13 has a significant added benefit over PCV7 in reducing carriage of ANSP.

150 he potential additional impact of PCV13 over PCV7 on reducing ANSP carriage.

151 ing the preceding period of heptavalent PCV (PCV7) use, overall and by serotype category.

152 we measured schedule-specific 7-valent PCV (PCV7) and 13-valent PCV (PCV13) effectiveness against va

153 Although the introductions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with dec

154 least 3 or at least 4 doses of 7-valent PCV (PCV7) from the state immunization registry.

155 -specific total IPD, PCV13 non-7-valent PCV (PCV7) serotypes, and PnCAP by Indigenous status.

156 with the historical risk after 7-valent PCV (PCV7) vaccination and using chart-validation.

157 The 7-valent PCV (PCV7) was introduced to the Israeli National Immunizatio

158 re and after administration of 7-valent PCV (PCV7) were available from England and Wales, the Netherl

159 serotypes contained in the seven-valent PCV (PCV7), and 9.5 years (6.1-16.6) for the grouped six addi

160 7-valent PCV (PCV7)/PCV13 vaccines were introduced in July 2009 and No

161 describe the impact on IPD of 7-valent PCV (PCV7; introduced in 2006) and PCV13 (introduced in 2010)

162 Three subperiods were defined: pre-PCV, PCV7, and PCV13.

163 Three sub-periods were established: pre-PCV, PCV7, and PCV13.

164 tiated at the time of 7- and 13-valent PCVs (PCV7; PCV13) implementation.

165 After pediatric PCV7 adoption, the median differential was 24.4% (P < .0

166 Ten years after pediatric PCV7 authorization, IPD due to PCV7 serotypes had decrea

167 ases per 100 000 population before pediatric PCV7 use and 6.4 afterward (P = .52).

168 Both PPV23 and herd immunity from pediatric PCV7 were associated with reductions in IPD in immunocom

169 ype distribution before widespread pediatric PCV7 use, the median differential between the 23 and 13

170 za was circulating, the efficacy of TIV plus PCV7 was 72.4% (95% confidence interval, 30.2%-89.1%) ag

171 rs old, overall IPD decreased by year 1 post-PCV7 (RR 0.55, 95% CI 0.46-0.65) and remained relatively

172 e-PCV7 (July 1998 to December 2004) and post-PCV7 (January 2005 to June 2011) periods, adjusting for

173 observed by expected IPD rates for each post-PCV7 year.

174 re-PCV7 period to obtain an estimate of post-PCV7 disease incidence.

175 re was pre-vaccination (serotype 14) or post-PCV7 (serotype 19A), suggesting that future vaccines wit

176 increased (41%-43% vs 56%-57%) pre- vs post-PCV7.

177 of 23% in all-cause pneumonia 7-9 years post-PCV7 introduction reported for adults aged >/=85 years i

178 Relative to PPSV23, PCV7 induced greater OPK at both 1 and 2 years for 6 of

179 -age incidence of IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR 0.61, 95% CI 0.59-0.63) but

180 -age incidence of IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR, 0.61 [95% confidence interv

181 and June, 2014, versus the pre-PCV13 and pre-PCV7 baseline.

182 modeling of pre-PCV7 rates or averaging pre-PCV7 rates.

183 ic-nonsusceptible IPD rates remain below pre-PCV7 rates for children <5 and adults >/=65 years old.

184 nded mainly by genes already circulating pre-PCV7.

185 ng either Poisson regression modeling of pre-PCV7 rates or averaging pre-PCV7 rates.

186 and meta-analysis to obtain the odds of pre-PCV7 VT carriage in the respective settings.

187 The odds of pre-PCV7 VT IPD, PCV schedule, PCV coverage and whether a ca

188 spitalization rates by age group for the pre-PCV7 (July 1998 to December 2004) and post-PCV7 (January

189 When compared with the pre-PCV7 baseline, there was a 56% overall reduction in inva

190 f IPD caused by each serotype during the pre-PCV7 period to obtain an estimate of post-PCV7 disease i

191 The pre-PCV7 proportion of VT carriage and IPD are the main dete

192 The pre-PCV7 proportion of VT IPD alone also had limited predict

193 thy infants were randomized (1:1) to receive PCV7 or PCV13 at ages 2, 4, 6, and 12 months; NP swabs w

194 Both group 2 and 3 received PCV7 at 2, 3 and 4 months.

195 rol group and comprised infants who received PCV7 after 6 months and came from unvaccinated communiti

196 ected to have an indirect effect of reducing PCV7 serotype maternal colonization and possibly disease

197 South Africa replaced PCV7 with PCV13 in 2011 using a 2 + 1 schedule.

198 have been expected if PCV13 had not replaced PCV7.

199 In 2010, PCV13 replaced PCV7 in the US immunisation schedule.

200 A 13-valent vaccine (PCV13) replaced PCV7 in 2010.

201 of age; a 13-valent vaccine (PCV13) replaced PCV7 in 2011.

202 umococcal conjugate vaccine (PCV13) replaced PCV7 in many jurisdictions; a comparative assessment of

203 umococcal conjugate vaccine (PCV13) replaced PCV7.

204 countries replacing or considering replacing PCV7 with PCV13, as well as data that can be used to eva

205 We evaluated the impact of replacing PCV7 with PCV13 on disease burden in adults and identifi

206 umococcal disease incidence, while replacing PCV7 with PCV13 would cause an overall decrease.

207 ly in children <3 years following sequential PCV7/PCV13 introduction.

208 nation against seven pneumococcal serotypes (PCV7) reduced disease prevalence due to antibiotic-resis

209 riage prevalence decreased in all ages since PCV7 introduction; vaccine-serotype carriage has been ne

210 iotic receipt, we measured schedule-specific PCV7/13 effectiveness against vaccine-serotype colonizat

211 ition and prevalence of NP colonization than PCV7 did for 4 additional PCV13 serotypes, and serotypes

212 This study indicates that PCV7 may have an immunological advantage over 23vP in ad

213 Subsequent studies showed that PCV7 provided cross-protection against serotype 6A but n

214 and PET insertion rates increased during the PCV7 years and declined after PCV13 introduction.

215 accine effectiveness was 90% (34-98) for the PCV7 serotypes and 73% (55-84) for the six additional se

216 D due to serotype 6C disease expanded in the PCV7 era.

217 ], respectively) in a 2-step pattern: In the PCV7 period, only OM caused by PCV7 + 6A serotypes was d

218 rotection) and also showed a reversal of the PCV7 era increase in paediatric empyema related to strai

219 The highly effective introduction of the PCV7 pneumococcal vaccine in 2000 in the United States(2

220 y lower in the PCV13 group compared with the PCV7 group; the main serotypes contributing to this sign

221 Over the same timeframe, PCV7 serotype disease incidence declined to </=1 case pe

222 nd no evidence of pneumococcal adaptation to PCV7 via downregulation or deletion of vaccine-serotype

223 .0%) protection against CAAP attributable to PCV7-serotype pneumococci.

224 PCV failure is rare and, compared to PCV7 serotypes, the additional PCV13 serotypes are more

225 cteristics, or outcomes of PCV13 compared to PCV7 vaccine failure.

226 nvasive pneumococcal disease (MR-IPD) due to PCV7 serotypes (6B, 9V, 14, 19F, and 23F).

227 The incidence of IPD due to PCV7 serotypes decreased in all ages after PCV7 introduc

228 ter pediatric PCV7 authorization, IPD due to PCV7 serotypes had decreased by 90% (95% CI, 77%-96%) in

229 1-2013, the overall incidences of IPD due to PCV7 serotypes, the 6 additional serotypes in PCV13, and

230 odeficiency virus were more often exposed to PCV7 serotypes by their mothers, their risk of acquisiti

231 creasing trend in disease incidence prior to PCV7 introduction in England and Wales, and (ii) a range

232 s remains lower than rates reported prior to PCV7 introduction in England.

233 Prior to PCV7 introduction, IPD incidence in infants aged <90 day

234 indings provide reassurance that, similar to PCV7, PCVs with additional serotypes can also prevent tr

235 Incidence in the pre-universal PCV7 (2002-2004), early PCV7 (2005-2007), pre-PCV13 (200

236 Incidence in the pre-universal PCV7 (2002-2004), early-PCV7 (2005-2007), pre-PCV13 (200

237 ad use of the pneumococcal conjugate vaccine PCV7.

238 roduction of pneumococcal conjugate vaccine (PCV7 and PCV13).

239 7), 7-valent pneumococcal conjugate vaccine (PCV7) (2008-2010), and PCV13 (2011-2013) periods were es

240 ith 7-valent pneumococcal conjugate vaccine (PCV7) accounted for 25% of UAD-positive isolates.

241 of 7-valent pneumococcal conjugate vaccine (PCV7) and 13-valent pneumococcal conjugate vaccine (PCV1

242 the 7-valent pneumococcal conjugate vaccine (PCV7) based on serological noninferiority criteria.

243 sal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 20

244 heptavalent pneumococcal conjugate vaccine (PCV7) has significantly reduced the burden of pneumococc

245 ith 7-valent pneumococcal conjugate vaccine (PCV7) immunized children, N = 567, enrolled between Nove

246 f a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vac

247 heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced macrolide-resistant invasive pneum

248 heptavalent pneumococcal conjugate vaccine (PCV7) in 2000, but its effect on pneumococcal meningitis

249 of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among adults has decline

250 ric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.

251 st offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a boos

252 ced 7-valent pneumococcal conjugate vaccine (PCV7) in April 2009 using a 2 + 1 schedule (6 and 14 wee

253 f a 7-valent pneumococcal conjugate vaccine (PCV7) in childhood immunization programs.

254 the 7-valent pneumococcal conjugate vaccine (PCV7) in September 2006 has markedly reduced the burden

255 of 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, epidemiology of pneumococcal

256 of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs.

257 of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. childhood immunization schedule in 2

258 the 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) in infants

259 seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and the bacterial compone

260 Non-7-valent pneumococcal conjugate vaccine (PCV7) serotypes other than 19A accounted for 40% of thes

261 the 7-valent pneumococcal conjugate vaccine (PCV7) transmitted by their mothers than vice versa; howe

262 n a 7-valent pneumococcal conjugate vaccine (PCV7) trial.

263 of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children.

264 12 years of pneumococcal conjugate vaccine (PCV7) use on pneumococcal nasopharyngeal carriage and se

265 , a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 with a three-dose schedule

266 seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the USA and resulted in dramatic

267 seven-valent pneumococcal conjugate vaccine (PCV7) were associated with changes in the rate of hospit

268 the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (PCV13), partly base

269 of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease (IPD) rates among b

270 ing 7-valent pneumococcal conjugate vaccine (PCV7)-era (2006-2010) and PCV13-era (2011-2014) birth co

271 of 7-valent pneumococcal conjugate vaccine (PCV7).

272 of 7-valent pneumococcal conjugate vaccine (PCV7).

273 nted by PCVs.Pneumococcal conjugate vaccine (PCV7/PCV13) implementation resulted in significant decli

274 of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infancy followed by 23-valent pneumoco

275 he 7-valent pneumococcal conjugated vaccine (PCV7) has affected the genetic population of Streptococc

276 uction of the 7-valent pneumococcal vaccine (PCV7) are sparse, especially in adults.

277 mothers) plus 7-valent pneumococcal vaccine (PCV7; delivered to infants) was higher than the efficacy

278 jugated pneumococcal polysaccharide vaccine (PCV7) is safe and induced greater serotype-specific immu

279 jugated pneumococcal polysaccharide vaccine (PCV7) were also associated with reduced prevalence of di

280 vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additiona

281 se in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13

282 immunisation with the seven-valent vaccine (PCV7), but its potential for herd protection and serotyp

283 on established for the seven-valent vaccine (PCV7).

284 d 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altered pneumococcal serot

285 d 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are highly effective in pr

286 d 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13).

287 ood immunization programs in 2002 (7-valent [PCV7]) and 2010 (13-valent [PCV13]).

288 nd trial compared the impact of PCV13 versus PCV7 on nasopharyngeal (NP) colonization and immunogenic

289 carriage survey (CSS5) in a community where PCV7 was first introduced in 2006 during a cluster rando

290 igated B-cell responses to establish whether PCV7 (a 7-valent PCV) induced T-dependent responses in a

291 caused by the PCV13 serotypes against which PCV7 has no effect (PCV13 minus PCV7).

292 STs commonly associated with PCV7 serotypes declined following PCV implementation, wi

293 It was comparable with PCV7 for all other common serotypes.

294 Compared with PCV7-immunized children, carriage among PCV13-immunized

295 ly from those causing invasive disease, with PCV7-associated serotypes overrepresented.

296 were inferior to Australian experience with PCV7 and reports from high-income countries giving a PCV

297 ons learned from a decade of experience with PCV7, the increasing problem of disease due to nonvaccin

298 Immunization with PCV7 has resulted in a substantial decline in pneumococc

299 ll responses to subsequent immunization with PCV7, when given after 23vP, were attenuated.

300 Lower rates of IPD were seen with PCV7 (IRR 0.45, 95% CI 0.38-0.54) and PCV13 serotypes (I